Cargando…
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes cont...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717557/ https://www.ncbi.nlm.nih.gov/pubmed/26782967 http://dx.doi.org/10.1186/s12885-016-2049-z |
_version_ | 1782410672411246592 |
---|---|
author | Kim, Eun Young Cho, Eun Na Park, Heae Surng Kim, Arum Hong, Ji Young Lim, Seri Youn, Jong Pil Hwang, Seung Yong Chang, Yoon Soo |
author_facet | Kim, Eun Young Cho, Eun Na Park, Heae Surng Kim, Arum Hong, Ji Young Lim, Seri Youn, Jong Pil Hwang, Seung Yong Chang, Yoon Soo |
author_sort | Kim, Eun Young |
collection | PubMed |
description | BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. RESULTS: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. CONCLUSIONS: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2049-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4717557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47175572016-01-20 Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma Kim, Eun Young Cho, Eun Na Park, Heae Surng Kim, Arum Hong, Ji Young Lim, Seri Youn, Jong Pil Hwang, Seung Yong Chang, Yoon Soo BMC Cancer Research Article BACKGROUND: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. METHODS: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. RESULTS: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. CONCLUSIONS: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2049-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-18 /pmc/articles/PMC4717557/ /pubmed/26782967 http://dx.doi.org/10.1186/s12885-016-2049-z Text en © Kim et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kim, Eun Young Cho, Eun Na Park, Heae Surng Kim, Arum Hong, Ji Young Lim, Seri Youn, Jong Pil Hwang, Seung Yong Chang, Yoon Soo Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title | Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title_full | Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title_fullStr | Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title_full_unstemmed | Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title_short | Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
title_sort | genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717557/ https://www.ncbi.nlm.nih.gov/pubmed/26782967 http://dx.doi.org/10.1186/s12885-016-2049-z |
work_keys_str_mv | AT kimeunyoung geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT choeunna geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT parkheaesurng geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT kimarum geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT hongjiyoung geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT limseri geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT younjongpil geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT hwangseungyong geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma AT changyoonsoo geneticheterogeneityofactionablegenesbetweenprimaryandmetastatictumorinlungadenocarcinoma |